Valuation: Elicio Therapeutics, Inc.

Market Cap 72.7M 62.94M 58.83M 53.77M 101M 6.93B 103M 690M 271M 3.47B 273M 267M 11.55B P/E 2026 *
-1.49x
P/E 2027 * -1.28x
Enterprise Value 72.7M 62.94M 58.83M 53.77M 101M 6.93B 103M 690M 271M 3.47B 273M 267M 11.55B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
69.16%
Yield 2026 *
-
Yield 2027 * -
1 week+8.39%
Current month+10.71%
1 month-10.92%
3 months-68.72%
6 months-64.37%
Current year-61.06%
1 week 3.04
Extreme 3.04
3.28
1 month 2.72
Extreme 2.72
3.48
Current year 2.66
Extreme 2.66
16
1 year 2.66
Extreme 2.66
16
3 years 2.66
Extreme 2.66
16
5 years 2.66
Extreme 2.66
24.39
10 years 2.66
Extreme 2.66
24.39
Manager TitleAgeSince
Chief Executive Officer 66 2018-09-30
Director of Finance/CFO 54 2025-03-23
Chief Tech/Sci/R&D Officer - 2025-11-18
Director TitleAgeSince
Director/Board Member 66 2018-09-30
Director/Board Member 54 2023-05-31
Chairman 71 2016-12-31
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Free

Chief Technology Officer

64,643 0.3387%
7/16/26 Free

Chief Technology Officer

52,832 0.2768%
7/16/26 Free

Chief Executive Officer

186,944 0.9795%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+8.39%-66.30%-69.00% 72.7M
+0.10%+3.85%+6.76%+16.75% 50.03B
-2.00%+5.79%+489.80%+582.43% 44.36B
+0.93%+12.55%+25.47%+83.91% 40.82B
+0.38%+6.55%+35.01%+10.60% 39.83B
+0.85%+10.32%+21.22%+47.64% 32.51B
-0.28%+4.51% - - 16.85B
+0.07%+5.23%+34.55%+126.74% 16.81B
-0.37%+1.39%+5.31%+21.15% 14.05B
+0.73%+18.73%+86.64%+29.61% 13.22B
Average +0.04%+251.54%+70.94%+94.43% 26.86B
Weighted average by Cap. +0.00%+294.95%+107.22%+138.60%

Financials

2026 *2027 *
Net sales - -
Net income -43.65M -37.79M -35.32M -32.28M -60.83M -4.16B -61.78M -414M -163M -2.08B -164M -160M -6.94B -57.33M -49.63M -46.39M -42.4M -79.9M -5.47B -81.15M -544M -213M -2.74B -215M -211M -9.11B
Net Debt - -
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
26-08-09 US$3.100 -2.82% 231,722
26-08-07 US$3.190 +1.59% 122,317
26-08-06 US$3.140 -1.57% 216,671
26-08-05 US$3.190 +0.95% 346,071
26-08-04 US$3.160 +10.49% 692,456
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.100USD
Average target price
20.00USD
Spread / Average Target
+545.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELTX Stock